AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04654286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer with HAM-AdMSC composite wrapping
Description: When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
Study NCT04247646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
Study NCT04247646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
Study NCT00140101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoMaxx™ Drug-Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT00140101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT03212443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve- axillary nerve block combination
Description: In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
Study NCT03212443 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subacromial infiltration
Description: In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
Study NCT01119352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
Study NCT01119352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension, once daily. Totally 8 doses
Study NCT02258399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity exercise
Study NCT02258399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise
Study NCT02258399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: Breakfast consumption
Study NCT00486642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT00486642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00486642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01845441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
Study NCT01845441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
Study NCT01845441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
Study NCT01459523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal placement
Description: Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study NCT00486642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01563029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: current asthma medicine
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study NCT01563029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone propionate
Study NCT01563029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00002879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study NCT01459523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short axis ultrasound
Description: Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study NCT01459523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long axis
Description: Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study NCT01459523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal placement
Description: Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
Study NCT02029027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GYNEFFIK(R)
Description: Vaginal electro-stimulation medical device
Study NCT02029027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
Study NCT00483171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-945,598
Description: CP-945,598
Study NCT00483171 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-pharmacological weight loss program (NPP)
Description: Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
Study NCT00483171 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Calorie Diet
Description: Low calorie diet
Study NCT02942017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of matching placebo for SAGE-547.
Study NCT01211613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
Study NCT01211613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanically-assisted manipulation
Description: Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
Study NCT01211613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care
Description: Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
Study NCT00357708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00357708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00357708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00357708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00426218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT00131573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bion
Description: battery powered bion microstimulator
Study NCT00131573 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bion
Description: battery powered bion microstimulator
Study NCT01396473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Policy and Environmental Change
Description: Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is administered to subjects
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is administered to subjects
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide is administered to subjects
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered with Carboplatin and Etoposide
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102
Description: AMG 102 is administered to subjects
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered to some subjects in combination
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is administered to some subjects in combination
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered to some subjects in combination
Study NCT00791154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered to some subjects in combination
Study NCT02139930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Control Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.
Study NCT02139930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Nicotine Reduction Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.
Study NCT02139930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Nicotine Reduction Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.
Study NCT05286983 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family Centred Care (FCC) interventions as potentially better practices (PBPs)
Description: After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness
Study NCT00352534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03981614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT03981614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02942017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547 90 μg/kg/h
Description: Intravenous infusion of SAGE-547
Study NCT03074578 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Watching Video-clip 1
Description: Video -clip 1 contains violent images and text
Study NCT03074578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Video-clip 1
Description: Video -clip 1 contains violent images and text
Study NCT03074578 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Watching Video-clip 2
Description: Video -clip 2 contains neutral images and text
Study NCT03981614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT02721212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring
Description: All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks.
Study NCT02721212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods.
Study NCT04002752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: Participants will receive JNJ-73763989 as single subcutaneous injection.
Study NCT04002752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
Study NCT02193620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
Description: Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
Study NCT02193620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft capsules
Description: Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
Study NCT02193620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dicofenac
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Study NCT02193620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicofenac
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Study NCT02580149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15).
Study NCT02580149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
Study NCT00765115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Study NCT00765115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02136173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heliosphere bag (air filled balloon)
Description: sequential balloons . Heliosphere bag (air filled balloon)
Study NCT02991209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Study NCT02991209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT02761564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Red blood cell tranfusion
Description: Red blood cell transfusion according to transfusion guidelines.
Study NCT02761564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ScvO2 measure
Description: ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
Study NCT04173221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician
Description: Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
Study NCT04173221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician
Description: Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
Study NCT02670993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing sessions.
Description: Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
Study NCT02670993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Painting sessions.
Description: Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
Study NCT02308865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi disciplinary palliative care monthly consultations
Description: multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
Study NCT03074578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Video-clip 2
Description: Video -clip 2 contains neutral images and text
Study NCT00920868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib at 50 mg PO BID)
Study NCT02348489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: Investigational medicinal product
Study NCT02348489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice
Description: Choice of one: cytarabine, decitabine, or azacitidine
Study NCT00127608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of clinical samples
Description: The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique.
Study NCT04268017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe Monitor
Description: For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device
Study NCT01639001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
Study NCT01639001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Cisplatin
Description: Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.